ES2172595T3 - Compuestos de 1-acil-4-alifatilaminopiperidina. - Google Patents

Compuestos de 1-acil-4-alifatilaminopiperidina.

Info

Publication number
ES2172595T3
ES2172595T3 ES95933394T ES95933394T ES2172595T3 ES 2172595 T3 ES2172595 T3 ES 2172595T3 ES 95933394 T ES95933394 T ES 95933394T ES 95933394 T ES95933394 T ES 95933394T ES 2172595 T3 ES2172595 T3 ES 2172595T3
Authority
ES
Spain
Prior art keywords
rent
sub
amino
replaced
alcoxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95933394T
Other languages
English (en)
Inventor
Silvio Ofner
Siem Jacob Veenstra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2172595T3 publication Critical patent/ES2172595T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS COMPUESTOS DE 1-ACIL-4ALIFATILAMINOPIPERIDINA, DE FORMULA (I), EN LA QUE R{SUB,1} ES UN RADICAL BENZOILO, NAFTOILO, O CICLOALCANOILO, SUSTITUIDO O SIN SUSTITUIR CON ALQUILO INFERIOR, ALCOXI INFERIOR, HALOGENO Y/O TRIFLUOROMETILO; R{SUB,2} ES CICLOALQUILO O UN RADICAL FENILO O NAFTILO, QUE ESTA SUSTITUIDO O NO SUSTITUIDO POR ALQUILO INFERIOR, ALCOXI INFERIOR, HALOGENO, NITRO, CIANO Y/O TRIFLUOROMETILO; R{SUB,3} Y R{SUB,4} UNIDOS, SON ALQUILENO INFERIOR O AZA-, OXA-, O TIA-ALQUILENO INFERIOR; O R{SUB,3} ES ALQUILO INFERIOR, ALCOXI INFERIOR-ALQUILO INFERIOR, DIALQUILAMINO INFERIOR-ALQUILO INFERIOR, O UN RADICAL DE FORMULA -(CH{SUB,2}){SUB,N}-C(=O)-R{SUB,5} (IA); Y R{SUB,4} ES HIDROGENO, ALQUILO INFERIOR, O UN RADICAL DE FORMULA -(CH{SUB,2}){SUB,N}C(=O)-R{SUB,5} (IA); R{SUB,5} ES (I) HIDROGENO, ALQUILO O ALQUILO SUSTITUIDO POR HALOGENO, ALCOXI INFERIOR, AMINO O AMINO SUSTITUIDO POR ALQUILO INFERIOR, AMINO-ALQUILO INFERIOR, NONOO DI-ALQUILAMINOALQUILO INFERIOR, ALCANOILO INFERIOR, ALCOXICARBONILO INFERIOR, O ALQUILENO INFERIOR O AZA-, OXA- O TIA-ALQUILENO INFERIOR, (II) HIDROXILO, CICLOALCOXI, ALCOXI INFERIOR O ALCOXI INFERIOR SUSTITUIDO CON ALCOXI INFERIOR, AMINO O AMINO SUSTITUIDO CON ALQUILO INFERIOR, AMINO-ALQUILO INFERIOR, MONO- O DI-ALQUILAMINO INFERIOR-ALQUILO, ALCANOILO INFERIOR, ALCOXICARBONILO INFERIOR, O ALQUILENO INFERIOR, O AZA-, OXA- O TIA-ALQUILENO INFERIOR, O (III) AMINO O AMINO SUSTITUIDO CON ALQUILO INFERIOR, CICLOALQUILO, AMINO-ALQUILO INFERIOR, MONO- O DI-ALQUILAMINOALQUILO INFERIOR, ALCANOILO INFERIOR, ALCOXICARBONILO INFERIOR O ALQUILENO INFERIOR, O AZA-, OXA- O TIA-ALQUILENO INFERIOR; X{SUB,1} ES METILENO, ETILENO, UN ENLACE DIRECTO, UN GRUPO CARBONILO LIBRE O CETALIZADO, O UN GRUPO HIDROXIMETILENO LIBRE O ETERIFICADO; Y N ES 0 O 1; ASI COMO SUS SALES, PROCEDIMIENTOS DE PREPARACION DE LOS COMPUESTOS DESCRITOS EN LA INVENCION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, Y SU UTILIZACION COMO INGREDIENTES FARMACEUTICAMENTE ACTIVOS.
ES95933394T 1994-09-30 1995-09-19 Compuestos de 1-acil-4-alifatilaminopiperidina. Expired - Lifetime ES2172595T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH296694 1994-09-30

Publications (1)

Publication Number Publication Date
ES2172595T3 true ES2172595T3 (es) 2002-10-01

Family

ID=4245651

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95933394T Expired - Lifetime ES2172595T3 (es) 1994-09-30 1995-09-19 Compuestos de 1-acil-4-alifatilaminopiperidina.

Country Status (14)

Country Link
US (1) US5935951A (es)
EP (1) EP0783490B1 (es)
JP (1) JPH10506399A (es)
AT (1) ATE212981T1 (es)
AU (1) AU3607895A (es)
CA (1) CA2198382A1 (es)
DE (1) DE69525355T2 (es)
DK (1) DK0783490T3 (es)
ES (1) ES2172595T3 (es)
FI (1) FI971260A7 (es)
HU (1) HUT77318A (es)
NO (1) NO971383L (es)
PT (1) PT783490E (es)
WO (1) WO1996010562A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW475930B (en) * 1995-04-24 2002-02-11 Novartis Ag Novel compound, its use and pharmaceutical composition comprising it
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW429256B (en) * 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
KR100821410B1 (ko) 2000-07-11 2008-04-10 에이엠알 테크놀로지, 인크. 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
DE10112198A1 (de) * 2001-03-14 2002-09-19 Gruenenthal Gmbh Substituierte Dimethyl-[1-(1-phenyl-cyclohexyl)-piperidin-3-ylmethyl]-amine
WO2003066589A1 (en) 2002-02-08 2003-08-14 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
NZ556628A (en) 2005-03-08 2009-09-25 Janssen Pharmaceutica Nv Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2060563A4 (en) * 2006-09-08 2010-12-22 Dainippon Sumitomo Pharma Co CYCLIC AMINO ALKYL CY CARBOXYL AMIDE DERIVATIVE
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AU2009222122A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2010239396B2 (en) * 2009-04-20 2016-06-23 Auspex Pharmaceuticals, Llc Piperidine inhibitors of Janus Kinase 3
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US20210015834A1 (en) 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8804104D0 (en) * 1988-02-23 1988-03-23 Glaxo Group Ltd Chemical compounds
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
EP0600952B1 (en) * 1991-08-20 1996-04-17 MERCK SHARP & DOHME LTD. Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
WO1995011895A1 (en) * 1993-10-26 1995-05-04 Ciba-Geigy Ag N-benzoyl-4-oxy/thio-2-substituted piperidines as substance-p receptor antagonists

Also Published As

Publication number Publication date
EP0783490B1 (en) 2002-02-06
AU3607895A (en) 1996-04-26
FI971260A0 (fi) 1997-03-26
CA2198382A1 (en) 1996-04-11
DE69525355D1 (de) 2002-03-21
HUT77318A (hu) 1998-03-30
DE69525355T2 (de) 2002-09-19
ATE212981T1 (de) 2002-02-15
PT783490E (pt) 2002-06-28
DK0783490T3 (da) 2002-05-13
FI971260A7 (fi) 1997-03-26
WO1996010562A1 (en) 1996-04-11
US5935951A (en) 1999-08-10
NO971383L (no) 1997-05-14
MX9702092A (es) 1997-10-31
JPH10506399A (ja) 1998-06-23
NO971383D0 (no) 1997-03-24
EP0783490A1 (en) 1997-07-16

Similar Documents

Publication Publication Date Title
ES2172595T3 (es) Compuestos de 1-acil-4-alifatilaminopiperidina.
ES2051719T3 (es) Un procedimiento para producir un compuesto de benzoilurea.
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
AR247070A1 (es) Composicion biocida que contiene una isotiazolinona y una urea
ES2196344T3 (es) Derivados de sulfonamida y su uso en el tratamiento de trastornos de snc.
ES8300088A1 (es) Procedimiento para preparar acilamilidas.
ES2135058T3 (es) Fosfito monodentado y composicion de catalizador a base de niquel para la hidrocianacion de monoolefinas.
ES2064310T3 (es) Procedimiento para preparar compuestos de imidazopiridina.
YU46738B (sh) Postupak za dobijanje benzodiazepina
ES2157366T3 (es) Derivados de pirimidindiona, pirimidintriona, triacindiona como antagonistas de receptores alfa-1-adrenergicos.
ES2150918T3 (es) 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas; compuestos intermedios y composiciones farmaceuticas.
DK0640592T3 (da) N-acylerede tricycliske azaheteroringe anvendelige som vasopressin-antagonister
PE20000339A1 (es) Biciclo [2.2.1] heptanos y compuestos relacionados
ES2054872T3 (es) Nuevos derivados de acido bencimidazolin-2-oxo-1-carboxilico utiles como antagonistas de los receptores 5-ht.
AR003429A1 (es) Antagonistas del receptor crf, composiciones que las contienen y el uso para la manufactura de medicamentos.
UY25300A1 (es) Composiciones conteniendo un antagonista alfa adrenérgico y un compuesto que eleva los niveles de cgmp para el tratamiento de la impotencia
ES2117281T3 (es) Nuevos analogos de la vitamina d.
AR246264A1 (es) Procedimiento para preparar esteres carbociclicos de hexahidro-8-hidroxi-2,6-metano-2h-quinolizin-3(4h)-ona.
ES2158840T3 (es) Nuevos analogos de adenosina carbociclicos utiles como inmunosupresores.
ES2132882T3 (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina 1.
ES2161718T3 (es) 2,5-dioxo-2,5-dihidro-1h-benzo(b)azepinas como antagonistas de los receptores de nmda.
ES2159345T3 (es) Indazolcarboxamidas.
ES2123812T3 (es) Derivados 1,5-benzodiazepina utiles como antagonistas de las cck o de la gastrina.
ES2166303B1 (es) Poliolefinas de mataloceno estabilizadas.
ES2059931T3 (es) Procedimiento para el tratamiento de la hipertrofia e hiperplasia cardiaca asi como vascular.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 783490

Country of ref document: ES